STAGE III UTERINE CORPUS LEIOMYOSARCOMA AJCC V8
Clinical trials for STAGE III UTERINE CORPUS LEIOMYOSARCOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE III UTERINE CORPUS LEIOMYOSARCOMA AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE III UTERINE CORPUS LEIOMYOSARCOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug cocktail aims to fight rare uterine cancer after chemo fails
Disease control OngoingThis study tests whether combining olaparib and temozolomide works better than standard drugs (trabectedin or pazopanib) for people with advanced uterine leiomyosarcoma that has spread or cannot be removed by surgery and has stopped responding to initial chemotherapy. About 74 pa…
Matched conditions: STAGE III UTERINE CORPUS LEIOMYOSARCOMA AJCC V8
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 23, 2026 11:56 UTC
-
New drug cocktail shows promise for rare sarcomas
Disease control OngoingThis phase II trial tests whether combining cabozantinib (a targeted therapy) with temozolomide (a chemotherapy drug) can slow tumor growth in people with advanced leiomyosarcoma or other soft tissue sarcomas that cannot be surgically removed or have spread. About 96 participants…
Matched conditions: STAGE III UTERINE CORPUS LEIOMYOSARCOMA AJCC V8
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 23, 2026 11:54 UTC
-
New drug combo shows promise for rare uterine cancer
Disease control OngoingThis study tests two drugs—olaparib and temozolomide—together in 23 people with advanced uterine leiomyosarcoma that has spread or cannot be removed by surgery. Olaparib blocks a protein that helps cancer cells repair themselves, while temozolomide damages cancer cell DNA. The go…
Matched conditions: STAGE III UTERINE CORPUS LEIOMYOSARCOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 19:02 UTC